Humoral immune response of BBIBP COVID‐19 vaccination before and after the booster immunization. Issue 8 (16th March 2022)
- Record Type:
- Journal Article
- Title:
- Humoral immune response of BBIBP COVID‐19 vaccination before and after the booster immunization. Issue 8 (16th March 2022)
- Main Title:
- Humoral immune response of BBIBP COVID‐19 vaccination before and after the booster immunization
- Authors:
- Cheng, Zhangkai J.
Huang, Huimin
Zheng, Peiyan
Xue, Mingshan
Ma, Jing
Zhan, Zhiqing
Gan, Hui
Zeng, Yifeng
Lin, Runpei
Li, Shiyun
Zhong, Ruifen
Li, Siping
Wang, Hongman
Sun, Baoqing - Abstract:
- Abstract: Background: The inactivated Sinopharm/BBIBP COVID‐19 vaccine has been widely used in the world and has joined the COVAX vaccine supply program for developing countries. It is also well adapted for usage in low‐ and middle‐income nations due to their low storage requirements. Objective: This study aims to report on the kinetics, durability, and neutralizing ability of the induced immunity of the BBIBP vaccine, and the intensified antibody response elicited by the booster. Methods: A total of 353 healthy adult participants, aged 20–74 years, were recruited in this multicenter study. A standard dose of the BBIBP vaccine was administered (Month 0), followed by a second standard dose (Month 1), and a booster dose (after Month 7). Vaccine‐induced virus‐specific antibody levels (SARS‐CoV‐2‐IgA/IgM/IgG), conventional virus neutralization test (cVNT), pseudovirus neutralization test (pVNT), and surrogate virus neutralization test (sVNT) were monitored over multiple time points. Results: Neutralizing titers induced by the two doses of inactivated vaccine for COVID‐19 peaked at Month 2 and declined to 33.89% at Month 6. Following the booster dose, elevated levels of antibodies were induced for IgA, IgG, and neutralizing antibodies, with neutralizing titer reaching 13.2 times that of before the booster. Conclusion: By monitoring the antibody titer levels postvaccination, this study has shown that serum antibody levels will decrease over time, but a notable spike in antibodyAbstract: Background: The inactivated Sinopharm/BBIBP COVID‐19 vaccine has been widely used in the world and has joined the COVAX vaccine supply program for developing countries. It is also well adapted for usage in low‐ and middle‐income nations due to their low storage requirements. Objective: This study aims to report on the kinetics, durability, and neutralizing ability of the induced immunity of the BBIBP vaccine, and the intensified antibody response elicited by the booster. Methods: A total of 353 healthy adult participants, aged 20–74 years, were recruited in this multicenter study. A standard dose of the BBIBP vaccine was administered (Month 0), followed by a second standard dose (Month 1), and a booster dose (after Month 7). Vaccine‐induced virus‐specific antibody levels (SARS‐CoV‐2‐IgA/IgM/IgG), conventional virus neutralization test (cVNT), pseudovirus neutralization test (pVNT), and surrogate virus neutralization test (sVNT) were monitored over multiple time points. Results: Neutralizing titers induced by the two doses of inactivated vaccine for COVID‐19 peaked at Month 2 and declined to 33.89% at Month 6. Following the booster dose, elevated levels of antibodies were induced for IgA, IgG, and neutralizing antibodies, with neutralizing titer reaching 13.2 times that of before the booster. Conclusion: By monitoring the antibody titer levels postvaccination, this study has shown that serum antibody levels will decrease over time, but a notable spike in antibody levels postbooster highlights the anamnestic immune response. This signifies that the protection capability has increased following the injection of booster immunization. Abstract : This study monitored specific antibody levels (IgA/IgM/IgG), cVNT, pVNT, and sVNT tests in 353 healthy adult subjects over the course of vaccination. The first two injections of the vaccine induce humoral responses with a peak at 2 months. Following the booster dose, IgA, IgG, and neutralizing antibodies increase with a neutralizing titer 13.2 times higher than before the booster.Abbreviations: cVNT, conventional virus neutralization test; Ig, immunoglobulin; pVNT, pseudo‐virus neutralization test; sVNT, surrogate virus neutralization test … (more)
- Is Part Of:
- Allergy. Volume 77:Issue 8(2022)
- Journal:
- Allergy
- Issue:
- Volume 77:Issue 8(2022)
- Issue Display:
- Volume 77, Issue 8 (2022)
- Year:
- 2022
- Volume:
- 77
- Issue:
- 8
- Issue Sort Value:
- 2022-0077-0008-0000
- Page Start:
- 2404
- Page End:
- 2414
- Publication Date:
- 2022-03-16
- Subjects:
- antibody persistence -- booster -- Coronavirus disease 2019 -- SARS‐CoV‐2 -- vaccine
Allergy -- Periodicals
616.97 - Journal URLs:
- http://estar.bl.uk/cgi-bin/sciserv.pl?collection=journals&journal=01054538 ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1398-9995 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/all.15271 ↗
- Languages:
- English
- ISSNs:
- 0105-4538
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 0790.945000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 23213.xml